![](/img/cover-not-exists.png)
PHP240 - HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS: COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?
Hnoosh, A., Courmier, D.F.Volume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.09.1134
Date:
October, 2018
File:
PDF, 374 KB
english, 2018